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Background: According to the International Multidisciplinary Classification of Lung Adenocarcinoma (LAD) by
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society
(IASLC/ATS/ERS) in 2011, the diagnosis of LAD is changing from simple morphology into a comprehensive
multidisciplinary classification. The aim of this study is to detect the expression of Notch-1 and analyze its
clinicopathological or prognostic significance in different histological subtypes of Lung Adenocarcinomas (LADs).
Methods: Western blot and Semi-quantitative Reverse transcription-polymerase chain reaction (RT-PCR) assays, as
well as immunohisitochemistry, were performed to detect the expression of Notch-1 in LAD cells and tissue
samples. Kaplan-Meier and multivariate Cox regression analyses were performed to evaluate the correlation of
Notch-1 expression with clinicopathological factors and prognosis of LAD patients.
Results: The expression level of Notch-1 protein in LAD cell lines or tissues was significantly lower than that in
normal human bronchial epithelial cell line (16HBE) or nontumor tissues (P < 0.05). By statistical analyses, it was
observed that negative Notch-1 expression was significantly associated with advanced clinical stage (P = 0.001) and
lymph node metastasis (P = 0.026) in LAD patients. Also, the recurrence rate of Notch-1-positive group was higher
than the Notch-1-negative group (P = 0.001), and patients with positive Notch-1 expression have a prolonged
progression of overall survival (P = 0.033). More interestingly, the expression of Notch-1 protein was often observed
to be negative in solid predominant adenocarcinoma (SPA) tissues, but highly expressed in papillary predominant
adenocarcinoma (PPA) and micropapillary predominant adenocarcinoma (MPA) tissues. Kaplan-Meier survival
analysis showed that patients with positive Notch-1 expression had a prolonged progression of overall survival
compared with those with negative Notch-1 expression (P = 0.033). The median survival time of Notch-1-positive or
negative patients was 64.6 months (95% CI: 31.497-97.703 months) or 36.0 months (95% CI: 12.132-59.868 months).
Conclusions: Notch-1 could be used as a predictable biomarker to be detected in different pathological and
histological subtypes in LAD for diagnosis or prognosis.
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Lung cancer is the most common cancer and the leading
cause of cancer deaths around the world [1]. Although
prognosis of patients can be improved through effective
treatment, the 5-year survival rate of patients with ad-
vanced lung cancer is only 10%-15% [2]. Non-small cell
lung cancer (NSCLC) accounts for 70%-80% in lung can-
cer, and among them, lung adenocarcinoma (LAD) ac-
counting for almost half of lung cancers, was one of the
most common histologic subtype. Patients with LAD
had rapid disease progression, and recurrence ratio was
high even after surgery. Despite the recent progresses
made in diagnostic techniques and combined treatments
for this disease, the overall 5-year survival rate of LAD
patients was still less than 30% [3-5]. Thus, a better un-
derstanding the molecular mechanisms involved in the
pathogenesis of LAD will be helpful for the development
of better prognostic markers and novel therapeutic tar-
gets to improve clinical treatment of LAD patients.
Recently, more and more studies gradually reveal that
dysregulation of the Notch signaling pathway plays a
pivotal role in the pathogenesis of many human malig-
nancies. Notch-1, one of the key receptor in the Notch
signaling pathway, encodes an important member of
Notch family proteins [6]. Increasing evidences have
shown that Notch-1 is involved in the regulation of
tumor cell growth, proliferation, apoptosis, metastasis
and chemo- or radioresistance. Notch-1 was either re-
ported as an oncogene [7] in some solid tumors, or re-
ported as a tumor suppressor in other tumors [8]. The
two different viewpoints were usually resulted from dif-
ferent types of tumors or different stages of tumors. For
example, some scholars showed that Notch-1 could be
activated to inhibit growth of small cell lung cancer cells,
while it was also found to promote growth of NSCLC
cells [9]. Depicted on the International Multidisciplinary
Classification of LAD by International Association for
the Study of Lung Cancer/American Thoracic Society/
European Respiratory Society (IASLC/ATS/ERS) pub-
lished in 2011 [10], the standard of diagnosis is refining
and adjusting to a comprehensive multidisciplinary clas-
sification. Thus, it is needed to detect the expression of
Notch-1 protein and analyze its clincopathological or
prognostic significance in different histological subtypes
of human LADs.
In the present study, Western blot assay was per-
formed to detect the expression of Notch-1 protein in
LAD cell lines and tissue samples. Also, immunohisto-
chemistry assay was performed to detect the expression
of Notch-1 protein in 101 cases of LAD tissues with dif-
ferent histological subtypes. Then, the correlations of
Notch-1 protein expression with clinicopathological fac-
tors of LAD patients were statistically analyzed. Add-
itionally, the relationships of Notch-1 with histologicalsubtypes and survival prognosis of LAD patients were
investigated.
Materials and methods
Patients and tissue samples
A total of 101 LAD tissues in Thoracic Surgery Depart-
ment of Jinling Hospital from January 2005 to December
2007 were collected. All patients have signed the In-
formed Consent. Every patient’s basic clinical records
were reviewed, including age, gender, operation time,
surgical site and related pathological data. The morpho-
logical classification and metastasis judgment were
determined by two senior pathologists. Cases were
followed up by the form of telephone, patients’ overall
survival (OS) time were defined from surgery to the date
of death or the latest follow-up. The deadline of follow-
up was September-15, 2012. This Research was granted
scientific and ethic approval by The Ethics Committee of
Jinling Hospital.
Cell lines
A normal human bronchial epithelial cell line (16HBE)
and three human LAD cell lines (SPC-A1, A549 and
H1299) were all purchased from the American type cul-
ture collection (ATCC). Tumor cells were expanded in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and ampicillin and streptomycin at 37°C in
a humidified atmosphere with 5% CO2, and 16HBE cell
line was maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) with 10% FBS and ampicillin and
streptomycin in the same environment.
Semi-quantitative reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA were extracted from different cultured cell
lines by TRIzol reagent (Invitrogen) following the manu-
facturer’s instructions. 1 ug RNA from each cell was pro-
vided to cDNA synthesis using oligo-dT as a primer by
PrimeScript™ RT reagent Kit (Takara). The procedure of
Reverse transcription reaction was 37°C for 15 min,
followed by 85°C for 5 seconds. The primers used for
amplification of Notch-1 were designed as followed:
Notch-1 sense, forward 5'-CCGTCATCTCCGACTTCA
TCT-3′and reverse 5'-GTGTCTCCTCCCTGTTGTTCTG-
3′. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was chosen to be inner control, forward sense 5’-GC
ACCGTCAAGGCTGAGAAC-3’ and reverse 5’-TGGTG
AAGACGCCAGTGGA-3’. PCR reactions were achieved
in the total volume of 25 ul mixture, including 9.5 μl of
H2O, 1 μl of forward and reverse primers, 1 μl of cDNA
and 12.5 μl of 2X SYBR Green PCR Master Mix. The
procedures of PCR were initial denaturation at 95°C for
3 min, then 35 cycles of duraturation at 94°C for 40 sec,
annealing at 58°C for 40 sec, elongation at 72°C for 90 s.
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products were captured by electrophoresis with 1.5%
agarose gel.
Western blot analysis
The fresh tissues were all random selected from Chest
surgery department of Jinling Hospital. All the cells and
tissue samples were lysed in ice-cold buffer containing
RIPA lysate with protease inhibitor cocktail and 1 mmol/L
Phenylmethanesulfonyl fluoride (PMSF) for about 20 min.
Proteins were fractionated by 4%-8% SDS- polyacrylamide
gel electrophoresis (SDS-PAGE), then followed by trans-
ferred to a polyvinylidene fluoride membrane, blocked by
5% non-fat milk with Tris-buffered salne. All blots were
probed with primary antibody rabbit anti-human Notch-1
(1:1000 dilution; Val1744; Cell signaling technology), while
rabbit anti-human β-actin (1:1000 dilution; 13E5; Cell
signaling technology) was used as control. The membrane
subsequently incubated with horseradish peroxidase
(HRP)-links second antibodys after 4°C overnight. Finally,
result was detected by ECL regent.
Immunohistochemistry
All specimens were fixed in 4% formalin and embedded
into wax blocks after surgery. The slides were treated
with poly-lysine to preventing tissue loss. 3–4 μm thick
consecutive paraffin sections were cut from each case
and stained with hematoxylin and eosin (H&E) and im-
munohistochemical analysis by Maxvision. Routinely
deparaffinized in xylene and decreasing concentrations
of ethanol to water. Antigen was fixed by high tempera-
ture and pressure with citrate buffer solution (Maixin_
bio MVS-0066). Each section was added 100 μl 3%
H2O2 to block endogenous peroxidase activity in room
temperature for 20 minutes. After washing by phosphate
buffer solution (PBS, Maixin_bio PBS-0060/0061), 100 μl
primary antibody (Santa cruze SC-6014, Notch-1) were in-
cubated at 4°C overnight. And then followed by polink-2
plus Polymer HRP detection system for Goat Primary
antibody (ZSGB-BIO, PV-9003), used reagent 1 100 μl
each section at room temperature for 20 minutes, later
washed off, reagent 2 was the same operation. Afterwards,
diaminobenzidine (DAB, biogenex, HK1240411) was used
as the color reagent before slides were counterstained with
hematoxylin, then dehydrated step by step by using de-
scending concertrations of ethanol, cleared with xylene,
mounted with neutral gum. Simultaneously, using PBS
(0.01 mol/L, PH = 7.4) instead of primary antibody as
blank control.
All the sides were independently assessed by two pa-
thologists. The immunostained results of Notch-1 pro-
tein were semi-quantitated according to the criteria
from published literatures [2,11]. Each section randomly
selected 5 high-power fields, positive cells representedby the percentage of totally number of similar cells. De-
tails were as follows: 0 point for less than 5% positive
cells; 1 for 5%-25% positive cells; 2 for 26%-50% positive
cells; 3 for 51%-75% positive cells; 4 for more than 76%
positive cells. The staining intensity was scored on a scale
as weak, moderate or strong. 0 point for no stained; 1 for
low stained (pale yellow); 2 for moderate stained (brown);
3 for strong stained (tan). After added the two scores, <3
was defined as negative, ≥3 was positive.
Statistical analysis
The statistical analyses were performed using software
SPSS version 17.0 (SPSS Inc, Chicago). Individual clin-
ical information and pathological characteristics were
summarized using descriptive statistics. Qualitative data
were determined a possible clear correlation analysis by
chi-square test or Fisher’s exact test if the number was
less than 5. Survival time was measured from the date of
surgery to the latest follow-up or the date of death. Uni-
variate analysis, including Survival analysis, was estimated
by Kaplan-Meier method. Log-rank test was used for
comparison of survival rate. Cox proportional hazards re-
gression model was used for multivariate analysis. P < 0.05
was considered to demonstrate statistical significance.
Results
Notch-1 expression in LAD cell lines or tissues
First, nuclear acid detection and Western blot assays
were performed to detect the expression of Notch-1 in a
normal human bronchial epithelial cell line (16HBE) and
three human LAD cell lines (SPC-A1, A549 and H1299).
As shown in Figure 1A and B, the relative expression
levels of Notch-1 mRNA and protein in LAD cell lines
were significantly lower than those in normal human
bronchial epithelial cell line. Next, the expression of
Notch-1 in 24 postoperative cases of randomly selected
LAD tissues and corresponding nontumor tissues was
detected. As shown in Figure 1C and D, the mean ex-
pression level of Notch-1 mRNA and protein in LAD
tissues were significantly lower than those in corre-
sponding nontumor tissues (P = 0.04). These data indi-
cated that downregulation of Notch-1 might play critical
roles in LAD development.
Clinicopathological variables of patients
Demographic, pathological and clinical variables were
collected as below. It contained 64 male and 37 female.
50 patients were below 60-year-old. The age of patients
at the time of diagnosis were ranging from 25 to 81-
year-old, the median was 58.83-year-old. 37 patients had
a smoking history in this 101 LAD cases. All the patients
had undergone curative resection of LAD, 58 tumors
(57.4%) were located in right, 43 ones (42.6%) were left.
39 cases (46.98%) relapsed, and 57 cases (56.4%) had
Figure 1 Expression of Notch-1 in LAD Cell lines and tissues. Semi-quantitative Reverse transcription-polymerase chain reaction (A) and
Western Blot (B) were used to detect expression of Notch-1 in different cells of lung adenocarcinoma. Brochial epithelial cell was used as control.
Weaker expression of Notch-1 was observed in tumor cells. Then, Notch-1 Protein in 24 tissues from surgery which diagnosed as lung adenocarcinoma
were detected by Western Blot (C and D). Each adjacent tissue from the same patient was used as control. Most of weaker performance was observed
in tumor ones (P= 0.04).
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International Cancer Control (UICC) TNM classification
of Malignant Tumours 7th edition [12] , there were 45
patients in stage I, 32 patients in stage II, 20 patients in
stage III, 4 patients in stage IV. Meanwhile, 44 cases were
poorly-differentiated, 47 were moderate-differentiated, and
10 were well-differentiated. By histological analyses [10],
41 patients were acinar predominant adenocarcinoma
(APA), 20 were papillary predominant adenocarcinoma
(PPA), 25 were solid predominant adenocarcinoma (SPA)
with mucin production, 15 were other types including
lepidic predominant adenocarcinoma (LPA), micropapil-
lary predominant adenocarcinoma (MPA) and adenosqua-
mous carcinoma. General clinical information of patients
was shown in Table 1.
Immunostaining of Notch-1 protein in LAD tissues
Immunohistochemistry was performed to detect the ex-
pression of Notch-1 protein in 101 cases of LAD tissues.
As shown in Figure 2 and Figure 3, the positive Notch-1
protein was predominantly located in the cell membrane
and (or) cytoplasmic, especially tumor cells. Brown
granular staining was deemed as positive performance
(black arrowheads). In 101 cases of LAD specimens, 36
(35.6%) cases were positive for Notch-1. Men were
accounted for 22 patients (61.1%) of the positive group,
whereas women were accounted for 14 patients (39.9%).
17 APA patients (38.6%), 9 PPA patients (45.0%) and 7
other subtypes of patients (58.3%) were confirmed as
positive, but only 3 SPA patients (12.0%) was were con-
firmed as positive (P = 0.021; Figure 4), suggesting that
immunostaining of Notch-1 in LAD tissues could behelpful for differentiating SPA from other histological
subtypes.
Correlation between Notch-1 expression and
clinicopathological factors of LAD patients
The correlations of Notch-1 expression and clinicopath-
ological factors of LAD patients were shown in Table 1.
The difference by statistical analyses indicated that both
clinical stages (P = 0.001) and recurrence of LAD patients
(P = 0.004) were aware of predominant relevance with sta-
tus of Notch-1 expression. Meanwhile, expression of
Notch-1 was also found to be significantly correlated with
histological subtypes (P = 0.021), tumor differentiation
(P = 0.05), lymph node metastasis (P = 0.026). The posi-
tive ratio of Notch-1 protein expression in tissues from
LAD patients with clinical stage I was significantly
higher than that in tissues from patients with other clin-
ical stages (II + III + IV). Also, tumors from LAD pa-
tients with positive Notch-1 expression showed better
differentiation than those from patients with negative
Notch-1 expression. Furthermore, the expression of
Notch-1 protein was observed to be closely correlated
with the survival endings of LAD patients (P = 0.047), and
patients with positive Notch-1 expression had better sur-
vival endings than those with negative Notch-1 expression.
Follow-up visit and prognostic factors analysis
In patients who were enrolled, the follow-up time was
from 0.7 to 77.1 months, the average was 38.1 months.
During the time of follow-up, 45 patients (44.6%) were
dead, 38 (37.6%) patients were alive, and 18 (17.8%) pa-
tients were lost. The mean 5-year survival rate of all
Table 1 Relationship between expression of Notch-1 and
clinicopathologic characteristics of LAD patients
Characteristics Notch-1
n (+) (-) x2 P
Gender 0.123 0.726
Male 64 22 42
Female 37 14 23
Age (year) 0.240 0.624
≥ 51 17 34
< 50 19 31
Histology 9.721 0.021*
APA 44 17 27
PPA 20 9 11
SPA 25 3 22
Others 12 7 5
Clinical stage 14.028 0.001**
I 45 25 20
II/III/V 56 11 45
Differentiation 3.850 0.05*
Poor 44 11 33
moderate 47 21 26
well 10 4 6
Lymph node Metastasis 4.963 0.026*
N0 44 21 23
N1-3 57 15 42
Recurrence 8.241 0.004**
present 39 10 29
absent 44 25 19
Smoking history 3.261 0.071
Non-smoker 64 27 37
smoker 37 9 28
Tumor location 0.08 0.777
Right 58 20 38
Left 43 16 27
Survival analysis 3.946 0.047*
Death 45 14 31
Live 38 20 18
Disconnect 18 2 16
Abbreviation: APA acinar predominant adenocarcinoma, PPA papillary
predominant adenocarcinoma, SPA solid predominant adenocarcinoma,
(+) positive; (-) negative. *P < 0.05, **P < 0.01.
Figure 2 The positive and negative expression of Notch-1 was
detected in lung adenocarcinoma specimens. It was not only in
tumors but also in adjacent alveolar and brochial epithelial tissues.
Black arrowheads indicated positive staining. Scale bar: 100 um.
Figure 3 Evaluation of Notch-1 IHC staining intensity. (A): no
staining, 0; (B): weak staining (pale yellow), 1+; (C): moderate staining
(brown), 2+; (D): strong staining (tan), 3+. The sections which pointed
with black arrows were considered as positve area. Scale bar: 100 um.
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curve was performed by life tables and shown in Figure 5.
Notch-1 positive and negative groups exhibited differ-
ences in survival curves which were shown in Figure 6A.
The median survival time of Notch-1-positive group was
64.6 months (95% CI: 31.497-97.703 months), but thatof the negative group was only 36.0 months (95% CI:
12.132-59.868 months). The five-year survival rate of
Notch-1-postive group (40.9%) was higher than that of
Notch-1-negative group (35.3%), and statistical signifi-
cance was exhibited (P = 0.033). Also, patients with dif-
ferent histological types showed different prognosis
(Figure 6B), and it was found that patients with SPA
showed worse survival than those with PPA, APA, LPA
and others (P = 0.002). At the same time, we also showed
that patients with no lymph node metastasis (N0) had
better survival than those with lymph node metastasis
(N1 + N2 + N3) (P = 0.021; Figure 6C). In addition, it
could be observed that patients with well tumor differ-
entiation had better survival than those with moderate
or poor tumor differentiation (P = 0.016; Figure 6D).
Figure 4 Expression of Notch-1 in different histopathological subtypes of lung adenocarcinoma. 17 APA patients (38.6%), 9 PPA patients
(45.0%) and 7 other subtypes of patients (58.3%) were confirmed as positive (arrows), most SPA patients were confirmed as negative (P = 0.021),
suggesting that immunostaining of Notch-1 in LAD tissues could be helpful for differentiating SPA from other histological subtypes. Scale bar = 100 um.
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parameters such as age, gender, histological phenotype
and others were included. As shown in Table 2, the status
of Notch-1 expression, along with histological phenotype,
lymph node metastasis and tumor differentiation, were
found to be significantly associated with survival of LAD
patients (P = 0.033, 0.002, 0.021 and 0.016, respectively).
For further investigation, we analyzed the prognostic fac-
tors mentioned above by a multivariate Cox regression
model (Table 2). The results indicated that only tumor dif-
ferentiation was observed to an independent prognostic
factor for LAD patients (P = 0.005). Although the status
of Notch-1 was not an independent prognostic factor
(P = 0.052), LAD patients with positive Notch-1 expres-
sion could show survival advantage.Figure 5 The overall survival curve of patients with lung
adenocarcinoma was done by life-tables. During the time of
follow-up, 45 patients (44.6%) were dead, 38 (37.6%) patients were
alive, and 18 (17.8%) patients were lost. The mean 5-year survival
rate of all patients was approximately 40%.Discussion
LAD is highly heterogeneous, and its level of differenti-
ation varies considerably. Sometimes, different parts of
the same tumor showed distinct characteristics. In this
research, the status of Notch-1 expression was observed
to be associated with clinical stage, histological subtypes
and survival outcomes of LAD patients.
Notch-1 was first found to associate with hemato-
logical diseases, and its expression level increased in
multiple myeloma, Hodgkin’s lymphoma, anaplastic
large cell lymphoma and acute myeloid leukemia [13,14].
Recently, Notch-1 was widely studied and reported to
aberrantly express in malignant tumors [15-19]. It was
considered as a highly controversial gene because of its
complex biological functions. Some researchers demon-
strated that the up-regulation of Notch receptors and li-
gands such as Notch-1 and Jagged-1 will probably
predict relatively metastasis in lung cancer [20]. Not-
withstanding that high expression of Notch-1 in a sub-
group of NSCLC cells might be reported as a poor
prognostic factor [9], different people hold different
views. Zheng et al. found that overexpression of Notch-1
could substantially cause A549, a typical LAD cell line,
to obtain cell cycle arrest and may suppress the growth
of cancer [21]. Coincidentally, although Notch-1 may
correlate with the prognosis of LAD patients in our
study, its expression was also affected by other factors.
The binary properties of Notch-1 which behaves as ei-
ther an oncogene or a tumor suppressor may possibly
depend on the developmental stages or various histo-
logical types in LAD patients [21]. Herein, in view of the
multidisciplinary classification of LAD, our data revealed
that expression of Notch-1 is significantly correlated
with histopathological subtypes of LAD. Some subtypes
were easily got stained while others, particularly in SPA,
were almost in a certain appearance of negative. On this
basis, the prognosis of different histological types indicated
Figure 6 Relationship between survival prognosis and related factors. (A): The correlation of Notch-1 expression and overall survival (OS) in
Lung adenocarcinoma patients. Patients with high Notch-1 expression had a prolong OS (The median survival time was 64.6 months (95% CI:
31.497-97.703) versus 36.0 months (95% CI: 12.132-59.868), P = 0.033); (B): The overall survival curves of different subtypes of lung adenocarcinoma.
(P = 0.002); (C, D): The overall survival curves of metastasis (P =0.021) and differentiation (P = 0.016).
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ulated by various factors during the development of LAD.
Although the histologic heterogeneity is exactly an under-
lying complexity, we still consider that Notch-1 could





Clinical stage (I/II + III + IV) 0.214
Tumor localization (Left/Right) 0.268
Tumor histology (APA/PPA/SPA/Others) 0.002*
Tumor differentiation (Poor/Moderate/Well) 0.016*
Lymph node metastasis (Present/Absent) 0.021*
Recurrence (Present/Absent) 0.383
Smoking history (Present/Absent) 0.053
Notch-1 expression (Positive/Negative) 0.033
RR: Relative risk, *P < 0.05.the expression linking with the subtypes is the reason why
it acts as a protect factor in patients outcomes. Better sur-
vival has already been corroborated in LPAs, APAs and
PPAs than in SPAs or MPAs, even though our selected
cases contain much more of the former three types thananalysis of prognostic factors in LAD patients
sis Multivariate analysis
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analysis results of Notch-1 which was not in conformity
with other literatures.
Interestingly, our results showed that the component
of Notch signaling pathway is activated in both normal
human alveolar or bronchial epithelium and lung tumor
samples. It is unexpectedly that the level of Notch-1 pro-
tein was downregulated in LAD cells or tissues. The
most reasonable explanation is what has been docu-
mented that Notch-1 could be trigged by hypoxia. Hyp-
oxia acts as one of the major stimuli, the tumor
microenvironment dramatically enhance Notch signaling
in the progression of lung cancer, as well as many other
types of tumorigenesis [22]. Expression levels of Notch
signaling components in human lung cells, especially in
primary bronchial epithelial and small airway epithelial,
reflect observations in surgical specimens, yet lung
tumor cell lines showed weakly positive, such as Notch-
1. Chen’s results strengthen a strong nuclear staining for
Notch-1 intracellular domain in lung epithelia, whereas
adenocarcinoma samples manifested decreased NICD-1,
even undetectable vision in some tumor areas. Neverthe-
less, hypoxia would dramatically activate the Notch sig-
naling pathway in LAD cells, oxygen concertrations
were contributed to regulate Notch activity in lung can-
cer [23]. Hypoxia may not only maintain malignant phe-
notypes of tumor cells but also cause poor response to
treatment. This suggested that the functions of Notch
pathway components in human LADs might be greatly
influenced by tumor microenvironment.
Recently, it has been widely accepted that the dysregu-
lation of the Notch signaling pathway existed in a variety
of human tumors. Lung cancer has been characterized
by a wide range of histological types. The heterogeneity
of lung cancer, especially in NSCLC, had appeared obvi-
ously. Sometimes, a single one tumor may concurrently
contain both adenocarcinoma behavior and squamous
carcinoma performances. The differentiation may from
startlingly well differentiated to entirely undifferentiated
at the same time. As a receptor of Notch signaling path-
way, Notch-1 was recommended as a vital factor in
growth and development of various tumors. Some drugs
which targeting the Notch signaling pathway has been
taken into the clinical trials, used in the treatment of
Alzheimer's disease and solid tumors [24,25]. Herein,
our results demonstrated that the expression of Notch-1
was co-associated with histological types of LAD pa-
tients. Although Notch-1 could not be an independent
prognostic factor, we propose that it would be a signifi-
cant predictive indicator, which was used to differentiate
histological type of LADs. Moreover, Notch-1 was actu-
ally a contradiction community. It could exert different
biological functions which influenced by many unknown
factors, and this need to be further studied.All the possible reasons were verified by more and
more researchers. The function of Notch-1 was also
found to be required for tumor initiation via regulating
P53 stability. The results of Licciulli implicated that
Notch-1 was a pivotal effector in Kras-driven Lung
adenocarcinoma and a critical P53 regulator at a post-
translational level [26]. Of interest, just like Kluk de-
tected NICD1 staining in 151 NSCLCs, none of them
showed diffuse strong staining. Thus, activation of
Notch-1 doesn’t appear to be common in some solid
tumors [27].
Taken together, downregulation of Notch-1 might be
correlated with LAD development. Although Notch-1
was not an independent prognostic factor, it could be
used as a predictable biomarker to be detected in dif-
ferent pathological and histological subtypes in LAD
patients. Also, LAD patients with positive Notch-1 ex-
pression tend to have a prolong survival time. On the
other hand, Notch-1 expression was figured out to asso-
ciate with histological subtypes of LAD, which had to-
tally disparate outcomes. Although further certification
was needed, we still believe that the multiple roles of
Notch-1 in NSCLC biology as well as its complex mech-
anisms should be further investigated in future.
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